Identification of Peptide Ligands for Targeting to the Blood-Brain Barrier

Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, P.O. Box 80082, 3508 TB, Utrecht, The Netherlands.
Pharmaceutical Research (Impact Factor: 3.42). 02/2010; 27(4):673-82. DOI: 10.1007/s11095-010-0053-6
Source: PubMed


Transport of drugs to the brain is limited by the blood-brain barrier. New, specific brain endothelium ligands can facilitate brain-specific delivery of drugs.
We used phage display in an in situ brain perfusion model to screen for new brain endothelium peptide ligands.
Two phage clones, displaying 15 amino acid-peptides (GLA and GYR) that were selected for brain binding in the mouse model, showed significant binding to human brain endothelium (hCMEC/D3), compared to a random control phage. This binding was not seen for other human endothelial cells (HUVEC). Binding to hCMEC/D3 cells was dose dependent. When phage GLA and GYR were individually perfused through the murine brain, their ability to bind to the brain was 6-fold (GLA) and 5-fold (GYR) higher than the control phage. When compared to lung perfusion, phage showed an 8.5-fold (GYR) and 48-fold (GLA) preference for brain over lung compared to the control.
These results indicate that two new peptide ligands have been identified that may be used for specific targeting of drugs to the blood-brain barrier.


Available from: Raymond Schiffelers
  • Source
    • "The honokiol was also administered to other male Sprague-Dawley rats ((8∼10 weeks old, 220∼260 g, n = 24) at a single dose of 20 mg/kg body weight via caudal vein. The time for respective 5 min, 30 min, 60 min and 120 min (Six rats per time point) post administration was designated to collect the cerebrospinal fluid (CSF), brain and other tissues after cardiac perfusion through left ventricle using the perfusion method described previously [38] to determinate exactly the amount of honokiol. Rats were perfused with Krebs-Henseleit buffer (118 mM NaCl, 14.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3, 10 mM D-glucose, pH 7.4) containing heparin (5 U/mL). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Gliosarcoma is one of the most common malignant brain tumors, and anti-angiogenesis is a promising approach for the treatment of gliosarcoma. However, chemotherapy is obstructed by the physical obstacle formed by the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB). Honokiol has been known to possess potent activities in the central nervous system diseases, and anti-angiogenic and anti-tumor properties. Here, we hypothesized that honokiol could cross the BBB and BCSFB for the treatment of gliosarcoma. METHODOLOGIES: We first evaluated the abilities of honokiol to cross the BBB and BCSFB by measuring the penetration of honokiol into brain and blood-cerebrospinal fluid, and compared the honokiol amount taken up by brain with that by other tissues. Then we investigated the effect of honokiol on the growth inhibition of rat 9L gliosarcoma cells and human U251 glioma cells in vitro. Finally we established rat 9L intracerebral gliosarcoma model in Fisher 344 rats and human U251 xenograft glioma model in nude mice to investigate the anti-tumor activity. We showed for the first time that honokiol could effectively cross BBB and BCSFB. The ratios of brain/plasma concentration were respectively 1.29, 2.54, 2.56 and 2.72 at 5, 30, 60 and 120 min. And about 10% of honokiol in plasma crossed BCSFB into cerebrospinal fluid (CSF). In vitro, honokiol produced dose-dependent inhibition of the growth of rat 9L gliosarcoma cells and human U251 glioma cells with IC(50) of 15.61 µg/mL and 16.38 µg/mL, respectively. In vivo, treatment with 20 mg/kg body weight of honokiol (honokiol was given twice per week for 3 weeks by intravenous injection) resulted in significant reduction of tumor volume (112.70±10.16 mm(3)) compared with vehicle group (238.63±19.69 mm(3), P = 0.000), with 52.77% inhibiting rate in rat 9L intracerebral gliosarcoma model, and (1450.83±348.36 mm(3)) compared with vehicle group (2914.17±780.52 mm(3), P = 0.002), with 50.21% inhibiting rate in human U251 xenograft glioma model. Honokiol also significantly improved the survival over vehicle group in the two models (P<0.05). This study provided the first evidence that honokiol could effectively cross BBB and BCSFB and inhibit brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. It suggested a significant strategy for offering a potential new therapy for the treatment of gliosarcoma.
    PLoS ONE 04/2011; 6(4):e18490. DOI:10.1371/journal.pone.0018490 · 3.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors studied the electric field distribution in flat cables as a function of dimensions and isolation materials. If the maximum electrical stress is higher than 25 kV/in, corona will be generated. The parametric study indicated that the electrical stress can be reduced by the proper selection of conductor dimensions, the use of semiconductive polytetrafluoroethylene (PTFE) material, and rounding off of the edges. The results of the calculations were verified by high-voltage tests in which the corona inception voltage of typical designs was measured. The calculated inception voltage correlated well with the measured voltage
    Electrical Insulation, Conference Record of the 1992 IEEE International Symposium on; 07/1992
  • [Show abstract] [Hide abstract]
    ABSTRACT: The problem of how a computer-based system could visually communicate to a driver how to proceed through a succession of intersections is addressed. Two different types of displays are compared: a traditional map display is used that shows the route to follow from a bird's eye view and in a global coordinate system; and a novel perspective display is developed that represents the driving instructions in a driver-centered coordinate system. Three related experiments are conducted, and the results indicate that a display that provides the driving instructions in a driver-centered framework performs best. These results lead to the proposal of a further display that combines the attractive features of both the map and the perspective display, thereby providing drivers with both a driver-centered and a global perspective
    Vehicle Navigation and Information Systems Conference, 1993., Proceedings of the IEEE-IEE; 11/1993
Show more